Request Speaker Information
Mass. Life Science By The Numbers
Massachusetts biopharma companies raised $2.1 billion in venture capital in Q3
8 Mass. companies went public in the first half, matching the combined total of 2024 and 2025
First half of 2026, had more lab leases than 2015-2019 first halves
Q3 year-to-date leasing up 20%, driven by renewals.
Speakers and Panels
What Tenants Want: Manufacturing & Lab Building Features Driving Demand
Which specs set a property apart for life science occupiers
)
Matt DeNoble
Senior Director, Life Science Investment Management
Greystar
)
Morgan Weinstein
EVP, Northeast Region
Phase 3 Real Estate Partners
)
John Sullivan
President of Architecture, Partner
SGA
Deal Environment and Leasing Strategies In Today’s Market
How owners are structuring transactions as vacancy stays elevated
)
Xave Jacoby
Managing Director
King Street Properties
)
Chris Maciejczak
SVP, Life Sciences
The Lightstone Group
Why You Should Attend This 2026 Boston Biotech Summit
What You'll Learn:
With 76% of first half biotech venture dollars going to later rounds, how do smaller companies compete ?
How is Boston’s biotech ecosystem continuing to foster innovation, and what distinctive advantages will support its rebound?
Massachusetts startups raised $10.2B in the first half of 2026. Where is that capital landing?
Are venture backed startups still the demand engine here, or has big pharma become the market's steadier tenant?
Boston still asks $76.72 per SF against $64.30 in San Diego. Is that premium defensible in 2027?
How is technology driving the demand for flexible, adaptable labs and GMP facilities that can evolve with science?
In what ways has tenant demand for modular layouts, spec suites, and shorter lease terms reshaped leasing dynamics in 2026?
Owners are investing in prebuilt lab suites and marketing beyond life sciences users. Is this approach is actually working?
How you'll do more business:
Connect with the industry leaders setting terms in Greater Boston right now. Understand what the current funding environment means for tenant quality, deal size and how long a company can commit. Gain insight into the manufacturing capabilities, GMP requirements and lab specifications that determine which buildings win real activity. Explore how owners are using rent, concessions and lease structure to compete in a tenant favorable market, and leave with a clearer read on where leverage sits heading into 2027.
Who attends:
Investors, owners, developers, tenants, end users, brokers, lawyers, designers, contractors, architects, property managers and more!
Why should you attend:
Bisnow events bring together the biggest power players in the industry to identify opportunities, build your network, and expand your business. With the largest audience of commercial real estate professionals in the world, no one knows how to help your business more than us.
For questions, recommendations, comments, or press inquiries please email our Senior Event Producer, Joshua Piquion at Joshua.Piquion@bisnow.com.
To request disability-related accommodations, please contact audrey.sullivan@bisnow.com no later than seven business days prior to the event.
Venue
David Rubenstein Treehouse at Harvard University
20 Western Ave
Boston, MA 02134
Agenda
| Time | Activity |
|---|---|
|
8:00 AM
9:00 AM
|
Coffee, Breakfast & Networking
|
|
9:00 AM
9:45 AM
|
What Tenants Want: Manufacturing & Lab Building Features Driving Demand
1.) Identify the lab space and specifications tenants prioritize when comparing available options. |
|
9:45 AM
10:30 AM
|
Deal Environment and Leasing Strategies In Today's Market
1.) Discuss Investment opportunities and what types of labs owners are trading on today. |
|
10:30 AM
10:45 AM
|
Post-Event Networking
|
Tickets
Sponsors
)
)
)
)